NCT04924062 2026-04-15
KEYNOTE-966
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
39 trialsNCT04003636 2026-03-24
KEYNOTE-966
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03693807 2026-02-06
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03768414 2026-01-12
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
SWOG Cancer Research Network
Phase 3 Completed
NCT03044587 2025-10-01
NIFE
AIO-Studien-gGmbH
Phase 2 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT03579771 2025-08-15
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Emory University
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02375880 2025-08-03
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
Leap Therapeutics, Inc.
Phase 1 Completed
NCT01862315 2025-03-19
Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01825603 2023-12-28
ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
University of Nebraska
Phase 1 Completed
NCT03684811 2023-11-18
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Novo Nordisk A/S
Phase 1/2 Completed
NCT03473574 2023-06-15
IMMUCHEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT03079427 2022-12-06
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
Asan Medical Center
Phase 2 Completed
NCT03102320 2022-06-30
ARCS-Multi
Bayer
Phase 1 Completed
NCT02392637 2022-02-02
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02128282 2021-10-22
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Senhwa Biosciences, Inc.
Phase 1/2 Completed
NCT02631590 2021-08-04
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01247337 2020-10-05
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma
Herlev Hospital
Phase 2 Completed
NCT01938729 2020-09-11
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03027284 2020-05-19
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00948935 2020-03-11
Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00779454 2020-02-06
Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma
Vejle Hospital
Phase 2 Completed
NCT01900158 2019-10-29
A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas
PCI Biotech AS
Phase 1 Completed
NCT02181634 2018-10-03
PrE0204
PrECOG, LLC.
Phase 2 Completed
NCT01912053 2018-05-11
MispheC
Center Eugene Marquis
Phase 2 Completed
NCT01043172 2018-01-03
A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection
National Cancer Center, Korea
Phase 2 Completed
NCT01320254 2017-10-12
PiCCA
Hannover Medical School
Phase 2 Completed
NCT01007552 2017-03-29
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
Roswell Park Cancer Institute
Phase 2 Completed
NCT01206049 2017-03-13
GOC-B-P
Vejle Hospital
Phase 2 Completed
NCT00753675 2016-10-10
VANGOGH
Sanofi
Phase 2 Completed
NCT01242605 2016-05-13
ABC-04
University College, London
Phase 1 Completed
NCT01267344 2016-05-04
BTC
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT01073839 2015-09-18
Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.
University of Zurich
Phase 1/2 Completed
NCT01389414 2015-05-28
Vecti-BIL
Fondazione del Piemonte per l'Oncologia
Phase 2 Completed
NCT00660699 2015-05-27
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
Washington University School of Medicine
Phase 2 Completed
NCT00660140 2013-08-13
Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00350961 2008-08-26
Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma
Rigshospitalet, Denmark
Phase 1/2 Completed
NCT00123825 2007-12-21
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
Dana-Farber Cancer Institute
Phase 2 Completed